KRAS and neoplasm: Of note, this patient had relatively low tumor shed throughout their disease course (maxVAF at each time point did not exceed 1%), and thus it is difficult to say exactly when the patient acquired the KRAS G12R alteration as it was only seen in cfDNA approximately one year following trastuzumab discontinuation.